Fatal Asymmetric Interstitial Lung Disease after Erlotinib for Lung Cancer

Publisher： Karger

E-ISSN： 1423-0356|84|5|431-435

ISSN： 0025-7931

Source： Respiration, Vol.84, Iss.5, 2012-08, pp. : 431-435

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fatal Interstitial Lung Disease after Addition of Sorafenib to a Patient with Lung Adenocarcinoma Who Had Failed to Improve with Erlotinib Alone

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-04 ,pp. : 273-276

Karger

Access to resources Recommend Favorite

Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-09 ,pp. : 464-466

Karger

Access to resources Recommend Favorite

Interstitial Lung Disease

By  

RESPIROLOGY (ELECTRONIC), Vol. 20, Iss. S3, 2015-12 ,pp. : 80-87

John Wiley & Sons Inc

Access to resources Recommend Favorite

Postoperative Pulmonary Complications after Surgery in Patients with Interstitial Lung Disease

By  

Respiration, Vol. 87, Iss. 4, 2014-02 ,pp. : 287-293

Karger

Access to resources Recommend Favorite

Panitumumab-Induced Interstitial Lung Disease in a Case of Metastatic Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 36, Iss. 4, 2013-03 ,pp. : 209-212

Karger

Access to resources Recommend Favorite